Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 4/2009

01-12-2009 | Commentary

Cost effectiveness of antiretrovirals — long term or short term?

Author: Professor Dr Steffen Flessa

Published in: Applied Health Economics and Health Policy | Issue 4/2009

Login to get access

Excerpt

HIV/AIDS is one of the greatest tragedies of the new millennium. No other disease has caused so much human suffering and has thrown back so many development efforts in such a short period. In particular, in sub-Saharan Africa, all attempts to roll back this disease, or at least to improve the situation of those living with it, have to be warmly welcomed. …
Literature
1.
Brandeau ML, Zaric GL. Optimal investment in HIV prevention programs: more is not always better. Health Care Manag Sci 2009; 12: 27–37PubMedCrossRef
2.
Marseille E, Kahn JG, Pitter C, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 2009; 7(4): 229–43PubMedCrossRef
3.
Bertozzi S, Pdian NS, Wegbreit J, et al. HIV/AIDS prevention and treatment. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. New York: Oxford University Press, 2006: 331–69
4.
Kahn JG, Marseille E, Auvert B. Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Medicine 2006 Dec; 3(12): e517
5.
Flessa S. Costing of health care services in developing countries: a prerequisite for affordability, sustainability and efficiency. In: Razum O, editor. Collection: challenges in public health. Vol 57. Frankfurt am Main: Peter Lang, 2009
6.
Betting on HIV prevention [editorial]. Lancet 2006; 368(9534): 424
7.
Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006 Aug 5; 368(9534): 489–504PubMedCrossRef
8.
Rauner MS, Brailsford SC, Flessa S. The use of discrete-event simulation to evaluate strategies for the prevention of mother-to-child transmission of HIV in developing countries. J Oper Res Soc 2005; 56: 222–33CrossRef
9.
Flessa S. Decision support for AIDS control programmes in Eastern Africa. OR-Spectrum 2003; 25: 265–91CrossRef
Metadata
Title
Cost effectiveness of antiretrovirals — long term or short term?
Author
Professor Dr Steffen Flessa
Publication date
01-12-2009
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 4/2009
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/BF03256156

Other articles of this Issue 4/2009

Applied Health Economics and Health Policy 4/2009 Go to the issue

Current Opinion

Which barriers prevent the efficient use of resources in medical device sectors?

Original Research Article

Cost savings associated with filling a 3-month supply of prescription medicines

Acknowledgments

Acknowledgement

Original Research Article

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine

Current Opinion

Assessing comparative effectiveness research in the US

Original Research Article

Demand for outpatient healthcare